↓ Skip to main content

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer

Overview of attention for article published in Cancer Discovery, February 2021
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#35 of 3,140)
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
21 news outlets
twitter
56 tweeters
wikipedia
1 Wikipedia page
reddit
1 Redditor

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer
Published in
Cancer Discovery, February 2021
DOI 10.1158/2159-8290.cd-20-1683
Pubmed ID
Authors

Francois Gonzalvez, Sylvie Vincent, Theresa E. Baker, Alexandra E. Gould, Shuai Li, Scott D. Wardwell, Sara Nadworny, Yaoyu Ning, Sen Zhang, Wei-Sheng Huang, Yongbo Hu, Feng Li, Matthew T. Greenfield, Stephan G. Zech, Biplab Das, Narayana I. Narasimhan, Tim Clackson, David Dalgarno, William C. Shakespeare, Michael Fitzgerald, Johara Chouitar, Robert J. Griffin, Shengwu Liu, Kwok-kin Wong, Xiaotian Zhu, Victor M. Rivera

Twitter Demographics

The data shown below were collected from the profiles of 56 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 21%
Other 5 21%
Researcher 5 21%
Student > Postgraduate 1 4%
Unknown 8 33%
Readers by discipline Count As %
Medicine and Dentistry 6 25%
Pharmacology, Toxicology and Pharmaceutical Science 2 8%
Biochemistry, Genetics and Molecular Biology 2 8%
Agricultural and Biological Sciences 2 8%
Chemical Engineering 1 4%
Other 1 4%
Unknown 10 42%

Attention Score in Context

This research output has an Altmetric Attention Score of 185. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 October 2021.
All research outputs
#135,437
of 19,430,502 outputs
Outputs from Cancer Discovery
#35
of 3,140 outputs
Outputs of similar age
#4,484
of 308,150 outputs
Outputs of similar age from Cancer Discovery
#3
of 88 outputs
Altmetric has tracked 19,430,502 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,140 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.8. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 308,150 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 88 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.